



**eureKING**

**Combined General Meeting of June 30, 2023**

**Voting results**

- **Number of shares:** 20 000 000
- **Total number of shares with voting rights:** 20 000 000
- **Total number of voting rights:** 20 000 000
- **Number of shares present or represented:** 12 018 149, representing 60.09% of the share capital
- **Number of votes present or represented:** 12 018 149, representing 60.09% of the voting rights

Resolutions	Votes expressed						Outcome
	Votes "in favour"		Votes "against"		Abstention		
	Vote	%	Vote	%	Vote	%	
<b>Ordinary shareholder's meeting</b>							
Resolution n°1 – Approval of the annual financial statements for the 2022 fiscal year	10 326 696	100	0	0	1 691 453	-	<b>Approved</b>
Resolution n°2 – Allocation of earnings for the fiscal year	10 326 696	100	0	0	1 691 453	-	<b>Approved</b>
Resolution n°3 – Approval of the report on the regulated agreements	7 534 426	95.54	351 895	4.46	1 691 453	-	<b>Approved</b>
Resolution n°4 – Approval of the information referred to in Article L. 22-10-9 I of the French <i>Code de commerce</i> contained in the corporate governance report (global <i>ex post say on pay</i> )	10 326 696	100	0	0	1 691 453	-	<b>Approved</b>
Resolution n°5 – Approval of the fixed, variable and exceptional components of overall compensation and benefits of any kind	10 326 696	100	0	0	1 691 453	-	<b>Approved</b>



# eureKING

paid or granted to Mr. Michael Kloss, Chief Executive Officer for the 2022 fiscal year							
Resolution n°6 – Approval of the compensation policy applicable to all of the Company's corporate officers for the 2023 fiscal year	10 326 696	100	0	0	1 691 453	-	<b>Approved</b>
Resolution n°7 – Approval of the compensation policy applicable to Mr. Michael Kloss, Chief Executive Officer, for the 2023 fiscal year	10 326 696	100	0	0	1 691 453	-	<b>Approved</b>
Resolution n°8 – Approval of the compensation policy applicable to the members of the Board of Directors for the 2023 fiscal year	10 326 696	100	0	0	1 691 453	-	<b>Approved</b>
Resolution n°10 - Powers for formalities	9 110 807	100	0	0	2 907 342	-	<b>Approved</b>
<b>Extraordinary shareholder's meeting</b>							
Resolution n°9 – Amendments to Articles 12.4.1 and 12.5 of the Company's articles of association	9 110 807	97.85	200 000	2.15	2 707 342	-	<b>Approved</b>



# eureKING

## About eureKING

Founded in March 2022, eureKING is a French SPAC (Special Purpose Acquisition Company) formed with the aim of acquiring European companies in the field of cutting-edge biomanufacturing, with the ambition of creating a leading bio-CDMO in Europe capable of meeting the growing outsourcing needs of this industry. eureKING has chosen to focus on three highly specialized and strategic segments of the biopharmaceutical industry: the production of biologics, in particular new generations of monoclonal antibodies or complex proteins, the production of cell and gene therapies and the production of live biotherapeutics (with applications in the microbiome).

With a €150 million capital raising in May 2022, eureKING is led by an international management team of experienced healthcare industry talent, 100% dedicated to the SPAC project and its development strategy. eureKING is supported by a Board of Directors with complementary pharmaceutical and financial expertise to achieve its goal of developing and promoting the promising biomanufacturing sector in Europe on an international scale.

eureKING is listed on the professional compartment of Euronext Paris since May 12, 2022.

[www.eureking.com](http://www.eureking.com)

## Media Contacts

**eureKING**

**Image Sept**

Leslie Jung-Isenwater / Sergio de la Calle / Florence Coupry

eureking@image7.fr

+33 (0)1 53 70 74 70